Alliancebernstein L.P. Cuts Holdings in Bruker Corporation $BRKR

Key Points

• Alliancebernstein L.P. has reduced its holdings in Bruker Corporation by 12.4%, selling 339,351 shares and now owning 2,390,366 shares valued at approximately $99.77 million.
• Bruker recently reported earnings of $0.32 per share for the quarter, missing expectations by $0.01, with revenue of $797.40 million, also below consensus estimates.
• The firm announced a quarterly dividend of $0.05 per share, representing an annual yield of 0.6%, with a payout ratio of 38.46%.

Alliancebernstein L.P. cut its holdings in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) by 12.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,390,366 shares of the medical research company's stock after selling 339,351 shares during the quarter. Alliancebernstein L.P. owned about 1.58% of Bruker worth $99,774,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Comerica Bank lifted its position in Bruker by 2.0% during the fourth quarter. Comerica Bank now owns 36,866 shares of the medical research company's stock worth $2,161,000 after acquiring an additional 734 shares during the last quarter. Mercer Global Advisors Inc. ADV bought a new position in shares of Bruker in the 4th quarter valued at $249,000. Ameriprise Financial Inc. grew its position in Bruker by 10.6% in the fourth quarter. Ameriprise Financial Inc. now owns 1,615,358 shares of the medical research company's stock valued at $94,692,000 after acquiring an additional 154,768 shares during the last quarter. BNP Paribas Financial Markets raised its stake in Bruker by 257.3% during the fourth quarter. BNP Paribas Financial Markets now owns 84,758 shares of the medical research company's stock worth $4,969,000 after acquiring an additional 61,036 shares in the last quarter. Finally, Captrust Financial Advisors lifted its holdings in shares of Bruker by 32.7% in the fourth quarter. Captrust Financial Advisors now owns 5,973 shares of the medical research company's stock worth $350,000 after acquiring an additional 1,472 shares during the last quarter. Institutional investors own 79.52% of the company's stock.

Bruker Stock Up 5.2%

NASDAQ BRKR traded up $1.58 on Thursday, hitting $32.07. 3,664,017 shares of the company were exchanged, compared to its average volume of 4,100,803. Bruker Corporation has a 12 month low of $28.53 and a 12 month high of $72.94. The company has a current ratio of 1.61, a quick ratio of 0.70 and a debt-to-equity ratio of 1.31. The company has a market cap of $4.87 billion, a PE ratio of 61.67, a PEG ratio of 4.23 and a beta of 1.21. The stock has a fifty day moving average of $36.25 and a 200-day moving average of $39.11.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). Bruker had a return on equity of 17.89% and a net margin of 2.31%.The firm had revenue of $797.40 million during the quarter, compared to the consensus estimate of $811.17 million. During the same quarter in the previous year, the company posted $0.52 EPS. The firm's revenue was down .4% on a year-over-year basis. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. As a group, analysts forecast that Bruker Corporation will post 2.69 earnings per share for the current year.

Bruker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 3rd. Stockholders of record on Tuesday, September 23rd will be issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Tuesday, September 23rd. Bruker's dividend payout ratio (DPR) is currently 38.46%.

Analyst Upgrades and Downgrades

BRKR has been the subject of several research analyst reports. Stifel Nicolaus set a $40.00 price target on shares of Bruker and gave the stock a "hold" rating in a report on Tuesday, August 5th. Bank of America lowered their target price on Bruker from $61.00 to $50.00 and set a "buy" rating for the company in a report on Thursday, June 26th. Jefferies Financial Group set a $60.00 target price on Bruker and gave the company a "buy" rating in a research report on Monday, August 4th. Barclays reduced their price target on Bruker from $46.00 to $43.00 and set an "overweight" rating on the stock in a report on Monday, August 4th. Finally, Citigroup dropped their price objective on shares of Bruker from $40.00 to $38.00 and set a "neutral" rating for the company in a report on Monday, August 4th. Five equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $51.30.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.